Neurogen Corporation Announces Results of Multiple Ascending Dose Studies with Experimental Obesity Drug

BRANFORD, Conn.--(BUSINESS WIRE)--Neurogen Corporation (Nasdaq: NRGN) today announced that it has completed the follow-up component of a Phase 1 multiple ascending dose (MAD) study with NGD-4715, an MCH-1 receptor antagonist being investigated for the treatment of obesity.

Back to news